% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • ezgi.ulusoy ezgi.ulusoy Dec 3, 2013 3:58 PM Flag

    Best bio stock for 2014

    Cop and paste from the street dated 27 nov 2013

    This week, I want to highlight what were, for me, some of the biggest surprises in the biotech sector of 2013 and speculate about what those same events might look like in 2014. Next week, I'll offer my own biotech stock predictions for 2014 -- a list that will surely come back to haunt me 12 months from now.

    Surprise No. 1 of 2013: The blow-up of approved, marketed drugs due to safety problems. Ariad Pharmaceuticals' (ARIA_) leukemia drug Iclusig pops immediately to mind in this category, but don't forget Affymax's anemia drug Omontys, no less of a disaster from earlier in the year. One doesn't usually plan for commercial-stage biotech companies completely blowing up, but that's exactly what happened to Ariad and Affymax to the surprise of most investors. The risk of a drug failure is something we more often associate with clinical trials, not drugs that make their way successfully through clinical trials and the FDA approval process. Yet in 2013, Ariad and Affymax managed to #$%$ failure from the jaws of victory.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.0750.0000(0.00%)May 27 2:44 PMEDT